VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 87 filers reported holding VAXCYTE INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,224,611 | -6.8% | 82,868 | -8.7% | 0.01% | 0.0% |
| Q2 2023 | $4,534,202 | +60.8% | 90,793 | +20.7% | 0.01% | +50.0% |
| Q1 2023 | $2,820,407 | -20.4% | 75,251 | +1.8% | 0.00% | -33.3% |
| Q4 2022 | $3,543,313 | +187.4% | 73,896 | +43.8% | 0.01% | +200.0% |
| Q3 2022 | $1,233,000 | +10.6% | 51,377 | +0.3% | 0.00% | 0.0% |
| Q2 2022 | $1,115,000 | +27.1% | 51,237 | +41.1% | 0.00% | +100.0% |
| Q1 2022 | $877,000 | -6.6% | 36,314 | -8.0% | 0.00% | 0.0% |
| Q4 2021 | $939,000 | -3.2% | 39,465 | +3.2% | 0.00% | 0.0% |
| Q3 2021 | $970,000 | -21.3% | 38,238 | -30.2% | 0.00% | -50.0% |
| Q2 2021 | $1,233,000 | +42.9% | 54,790 | +25.4% | 0.00% | +100.0% |
| Q1 2021 | $863,000 | +17.9% | 43,698 | +58.6% | 0.00% | 0.0% |
| Q4 2020 | $732,000 | -46.2% | 27,559 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $1,361,000 | – | 27,559 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |